echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Opdivo (nivolumab) combined with Cabometyx (cabozantinib) in the first-line treatment of advanced renal cell carcinoma, CHMP holds positive opinions

    Opdivo (nivolumab) combined with Cabometyx (cabozantinib) in the first-line treatment of advanced renal cell carcinoma, CHMP holds positive opinions

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bristol Myers Squibb announced today that the European Medicines Management Agency (EMA) Committee for Medicinal human use (CHMP) has recommended approval of the Opdivo® (nivolumab) and Cabometyx® (cabozantinib) in combination with first-line treatment of advanced renal cell carcinoma (RCC).


    management

    Dana Walker, head of Bristol Myers Squibb's Genitourinary Cancer Development Program, said: "In recent years, the field of renal cell carcinoma treatment has undergone changes, and many advances have helped improve the prognosis of patients.


    The positive opinion of CHMP comes from the positive results of the CheckMate-9ER Phase III trial.


    The progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) of patients in the sunitinib Opdivo (nivolumab) combined with Cabometyx (cabozantinib) group were significantly improved.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.